SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets

Area of Science:

• Bioinformatics
• Computational Biology
• Pharmacology

Background:

• Combinatorial therapies are crucial for improving anticancer treatment efficacy.
• Analyzing pre-clinical drug combination screening data is essential for drug discovery.
• Existing software may lack comprehensive interpretation and annotation capabilities.

Purpose of the Study:

• To report major updates to the SynergyFinder R package for enhanced analysis of drug combination screening results.
• To introduce novel features for improved interpretation, annotation, and visualization of synergy data.
• To provide a user-friendly tool and web server for the drug discovery community.

Main Methods:

• Extended mathematical models for higher-order drug combination data analysis.
• Implemented dimension reduction techniques for synergy landscape visualization.
• Integrated statistical analysis with confidence intervals and P values for synergy and sensitivity.
• Developed a synergy barometer for harmonizing multiple scoring methods.
• Enabled fast annotation of drugs and cell lines with chemical and target information.

Main Results:

• The updated SynergyFinder R package offers advanced analytical capabilities for drug combinations.
• New features provide statistical significance, consensus synergy metrics, and mechanism-of-action insights.
• Dimension reduction techniques enable effective visualization of complex synergy landscapes.
• Fast annotation of drugs and cell lines aids in understanding combination mechanisms.

Conclusions:

• The enhanced SynergyFinder R package provides a more robust and interpretable platform for pre-clinical drug combination studies.
• The integrated statistical analysis and annotation features facilitate unbiased interpretation of clinical potential.
• The accompanying web server (www.synergyfinderplus.org) democratizes access to advanced drug synergy analysis.